IN THE CLAIMS

1. (Currently Amended) A compound ~~Pyrrolo[2,1-c][1,4]benzodiazepine hybrid~~ of the formula given below wherein R is H or OH and n is ~~2-3~~ 2 or 3



~~n = 2-3~~
~~R = H, OH~~

where R' [[=]]is



or



2. (Currently Amended) A compound ~~Pyrrolobenzodiazepine hybrid~~ as claimed in claim 1 of the structure



3. (Currently Amended) A compound ~~Pyrrolobenzodiazepine hybrid~~ as claimed in

claim 1 of the structure



[[10]]

4. (Currently Amended) A compound ~~Pyrrolobenzodiazepine hybrid~~ as claimed in claim 1 of the structure



5. (Currently Amended) A compound ~~Pyrrolobenzodiazepine hybrid~~ as claimed in claim 1 of the structure



6. (Currently Amended) A compound ~~Pyrrolobenzodiazepine hybrid~~ as claimed in claim 1 of the structure



7. (Currently Amended) A compound ~~Pyrrolobenzodiazepine hybrid~~ as claimed in claim 1 of the structure



8. (Currently Amended) A compound ~~Pyrrolobenzodiazepine hybrid~~ as claimed in claim 1 of the structure



9. (Currently Amended) A compound ~~Pyrrolobenzodiazepine hybrid~~ as claimed in claim 1 of the structure



10. (Currently Amended) A process for the preparation of a compound of the formula wherein R is H or OH and n is ~~2-3~~ 2 or 3



~~n = 2-3~~
~~R = H, OH~~

where R' [[=]]is 

or 

the process comprising the steps of:

a) reacting ~~reacting~~ an acridone or an acridine acid with (2*S*)-N-[4-(n'-aminoalkyloxy)-5-methoxy-2-nitrobenzoyl]-pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula I



FORMULA I

in the presence of EDCI and HOBt in organic solvent for a period of 24 h to obtain (2*S*)-N-{4-[n'-(4"-acrido-nylcarboxamido)-alkyl]-oxy-5-methoxy-2-nitrobenzoyl} pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula II / (2*S*)-N-{4-[n'-(4"-acridinylcarboxamido)-alkyl]-oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula V where n 'n' is ~~2-3~~ 2 or 3[[,]]and R is H or OH;



FORMULA II



FORMULA V

b) isolating the compound of formula II/formula V, and

c) then reducing the compounds of formula II/formula V with $SnCl_2.2H_2O$ in presence of an organic solvent up to a reflux temperature[[,]];

d) isolating the (2*S*)-N-{4-[n'-(4"-acridonylcarboxamido)-alkyl]-oxy-5-methoxy-2-aminobenzoyl}pyrroli-dine-2-carboxaldehydediethylthioacetal of formula III/(2*S*')-N-{4-[n'-(4"-acridinylcarbox-amido)-alkyl]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula VI where n is ~~2-3~~ 2 or 3 and R is H or OH[[,]];



FORMULA III



FORMULA VI

and

e) reacting the compound of formula III/formula VI with a deprotecting agent to obtain the ~~desired pyrrolo[2,1-*c*][1,4]benzodiazepine hybrid~~ compound of formula



n is 2 or 3
R is H or OH

where R' = is



or



---

11. (Currently Amended) ~~A~~ The process as claimed in claim 10 wherein the organic solvent used for the reaction of the acridone/acridine acid with the compound of formula I comprises dimethyl furan.

12. (Currently Amended) ~~A~~ The process as claimed in claim 10 wherein the compound of formula II/formula V is isolated by washing with saturated $NaHCO_3$, brine, drying and ~~evaporation of~~ evaporating the solvent.

13. (Currently Amended) ~~A~~ The process as claimed in claim 10 wherein the organic solvent used during the reduction of compound of formula II/formula V comprises methanol.

14. (Currently Amended) ~~A~~ The process as claimed in claim 10 wherein the compound of formula III/formula V is isolated by adjusting the pH of the reaction mixture to about pH 8 with a saturated $NaHCO_3$ solution, diluting with ethyl acetate, filtering through celite and ~~extracted~~ extracting an organic phase and drying the organic phase over Na_2SO_4.

15. (Currently Amended) ~~A~~ The process as claimed in claim 10 wherein the deprotecting agent used for obtaining the compound of formula IV/formula VII comprises $HgCl_2$ and $CaCO_3$ in MeCN-water (4:1).

16. (Currently Amended) ~~A~~ The pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula given below wherein R is H or OH and n is ~~2-3~~ 2 or 3 and a pharmaceutically acceptable additive[[.]]



where R' [[=]]is



or



17. (Currently Amended) A method for the treatment of cancer wherein the cancer is selected from the group consisting of leukemia, non-small cell, lung, colon, CNS, melanoma, ovarian, renal, prostate and breast in a mammal ~~subject~~ suffering from the same comprising administering a pharmaceutically effective amount of a compound of the formula



~~n = 2-3~~
~~R = H, OH~~

where R' [[=]]is 

or 

wherein R is H or OH and n is 2-3 to the mammal.

18. (Cancel)

19. (Original) A method as claimed in claim 17 wherein the mammal is a human being.

20. (Cancel)

21. (Cancel)